Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PERCORTEN vs DILAUDID-HP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Percorten (desoxycorticosterone pivalate) is a synthetic mineralocorticoid that binds to and activates the mineralocorticoid receptor (MR) in the renal distal tubule, leading to increased sodium reabsorption, increased potassium and hydrogen ion excretion, and water retention, thereby expanding extracellular fluid volume and increasing blood pressure.
Hydromorphone is a full mu-opioid receptor agonist with high affinity for mu-opioid receptors, producing analgesia, euphoria, and sedation. It also binds to kappa and delta opioid receptors with lower affinity.
Adjunctive therapy in adrenocortical insufficiency (Addison's disease) for mineralocorticoid replacement,Off-label: Treatment of orthostatic hypotension due to autonomic dysfunction
Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate (FDA-approved),Off-label: Treatment of acute pain, postoperative pain, cancer pain, and breakthrough pain
1-5 mg intramuscularly or subcutaneously daily with dose adjusted based on clinical response and electrolyte monitoring.
Initial dose: 0.2-0.6 mg IV/IM/SC every 2-4 hours as needed; usual adult dose: 0.2-0.4 mg IV/IM/SC. Oral: 1-2 mg every 3-6 hours. Dose titration based on pain severity.
Terminal elimination half-life is approximately 30-40 minutes. Clinically, the short half-life necessitates frequent dosing (e.g., every 6-12 hours) to maintain therapeutic effect in mineralocorticoid replacement.
Terminal elimination half-life: 2.3–4 hours. In clinical context, consistent with dosing interval of 4–6 hours for immediate-release formulations; prolonged in hepatic or renal impairment.
Primarily hepatic via reduction and conjugation; excreted in urine as metabolites. Desoxycorticosterone pivalate is a prodrug that is hydrolyzed to desoxycorticosterone, which is then metabolized.
Hydromorphone is extensively metabolized in the liver via glucuronidation to hydromorphone-3-glucuronide (major metabolite) and to a lesser extent via reduction to dihydroisomorphine and dihydromorphine. Minor CYP2C9 and CYP3A4 involvement.
Renal (biliary/fecal negligible). Approximately 50-70% of a dose is excreted as metabolites in urine; <5% unchanged.
Renal: predominantly as hydromorphone-3-glucuronide (H3G), unchanged hydromorphone (<6%), and other metabolites. Biliary/fecal: minimal.
Approximately 90-94% bound to albumin and corticosteroid-binding globulin (CBG).
Approximately 20–30%, primarily to albumin.
Vd approximately 0.5-0.8 L/kg. Clinical meaning: Distributes primarily into extracellular fluid; low Vd indicates limited tissue penetration.
1.2–1.8 L/kg. Indicates extensive tissue distribution, consistent with a lipophilic opioid.
Oral: Approximately 50-70% (high first-pass metabolism). IM/SC: 100% (assumed).
Oral: 24–51% (first-pass metabolism); Intramuscular: 96% (relative to IV).
No specific GFR-based dose adjustments established; use with caution in renal impairment due to potential for fluid retention and hypertension.
GFR 30-60 m L/min: reduce dose by 25-50%; GFR 10-29 m L/min: administer 50-75% of normal dose every 6-8 hours; GFR <10 m L/min: administer 25-50% of normal dose every 8-12 hours.
No specific Child-Pugh based dose adjustments; caution in severe hepatic impairment due to reduced metabolism and increased risk of adverse effects.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce initial dose by 50%; Child-Pugh Class C: avoid use or reduce dose by 75% with extended dosing interval.
0.1-0.3 mg/kg intramuscularly or subcutaneously daily, divided every 12-24 hours, with titration based on clinical response.
Children >2 years: 0.1-0.2 mg/kg IV/IM/SC every 4-6 hours; maximum single dose 2 mg. Neonates/infants: 0.03-0.05 mg/kg IV/IM/SC every 4-6 hours.
Initiate at lower end of adult dose (1 mg daily) with careful monitoring for fluid overload and electrolyte disturbances due to age-related renal and cardiovascular changes.
Initial dose: 0.1-0.2 mg IV/IM/SC every 4-6 hours; reduce dose by 50% compared to younger adults; titrate cautiously due to increased sensitivity and risk of respiratory depression.
None
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and RISKS OF USE IN PATIENTS WITH HEAD INJURY OR INCREASED INTRACRANIAL PRESSURE.
May cause severe hypertension, edema, congestive heart failure, hypokalemia, or metabolic alkalosis. Monitor blood pressure, serum electrolytes, and body weight. Use with caution in patients with cardiac disease, renal impairment, or hepatic disease. Avoid excessive sodium intake.
Addiction, abuse, and misuse,Life-threatening respiratory depression,Accidental ingestion,Neonatal opioid withdrawal syndrome,Risks from concomitant use with benzodiazepines or other CNS depressants,Adrenal insufficiency,Severe hypotension,Gastrointestinal effects (constipation, ileus),Seizures,Withdrawal
Hypersensitivity to desoxycorticosterone or any component,Severe hypertension,Hyperkalemia,Edema or fluid overload states,Congestive heart failure,Severe renal impairment
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity to hydromorphone or any component of the product
Avoid high-potassium foods (e.g., bananas, oranges, salt substitutes) as Percorten increases potassium retention. Limit sodium intake to manage fluid balance.
Avoid alcohol while taking DILAUDID-HP, as it can potentiate CNS depression and increase the risk of respiratory depression. Grapefruit juice may inhibit CYP2D6 and CYP3A4 metabolism, potentially increasing hydromorphone levels; avoid concurrent consumption. High-fat meals may delay absorption; maintain consistent timing with or without food.
Percorten (desoxycorticosterone pivalate) is a mineralocorticoid. Data in pregnant women are limited. In animal studies, corticosteroids have been shown to be teratogenic. Use during pregnancy only if clearly needed. First trimester: Possible increased risk of cleft palate and intrauterine growth restriction. Second and third trimesters: Potential for adrenal suppression in the fetus/newborn.
FDA Pregnancy Category C. First trimester: No well-controlled human studies; animal studies have shown teratogenicity at high doses. Second and third trimesters: Chronic maternal use may lead to neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth. Avoid use during labor due to risk of neonatal respiratory depression.
Corticosteroids are excreted in breast milk in small amounts. Desoxycorticosterone pivalate specific data are lacking. M/P ratio not determined. At high maternal doses, monitor infant for signs of adrenal suppression. Use with caution.
Hydromorphone is excreted into breast milk. The milk-to-plasma (M/P) ratio is approximately 2.6. Limited data suggest low levels, but use caution due to potential for infant sedation and respiratory depression. The American Academy of Pediatrics considers hydromorphone compatible with breastfeeding if used short-term at low doses.
Pregnancy may increase clearance of corticosteroids, potentially requiring dose adjustments. However, specific pharmacokinetic data for Percorten are lacking. Use lowest effective dose and monitor clinical response and serum levels if available.
Pregnancy does not significantly alter hydromorphone pharmacokinetics, but dose adjustments may be needed due to increased pain or opioid tolerance. Use lowest effective dose for shortest duration. Monitor for respiratory depression and adjust accordingly.
Percorten (desoxycorticosterone pivalate) is a mineralocorticoid used for adrenal insufficiency. Monitor for hypertension, hypokalemia, and edema. Titrate dose based on blood pressure and serum potassium. Use with caution in heart failure or renal impairment.
DILAUDID-HP (high-potency hydromorphone) is indicated for opioid-tolerant patients only; 1 mg DILAUDID-HP is equivalent to 4 mg standard hydromorphone. Use with extreme caution in patients with respiratory compromise, COPD, or cor pulmonale. Avoid in patients with paralytic ileus or suspected GI obstruction. Monitor for serotonin syndrome when co-administered with serotonergic drugs. For PCA use, ensure proper programming to prevent overdose. Naloxone is the reversal agent; may require higher doses due to high potency.
Take exactly as prescribed; do not miss doses.,Report rapid weight gain, swelling, or shortness of breath.,Avoid excessive salt intake; follow a low-sodium diet if advised.,Do not stop abruptly; taper under medical supervision.
This is a high-potency opioid; take exactly as prescribed and never increase dose without consulting your doctor.,Do not break, crush, or chew tablets; swallow whole to avoid rapid release of the drug.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sedatives) as they can increase the risk of severe drowsiness, respiratory depression, and death.,Do not stop taking abruptly; withdrawal symptoms may occur. Consult your doctor for a tapering plan.,Constipation is a common side effect; maintain adequate fluid intake, fiber, and consider stool softeners or laxatives as needed.,Store securely out of reach of children and pets; properly dispose of unused medication at a take-back location.,Seek emergency medical attention if you experience difficulty breathing, extreme drowsiness, confusion, or fainting.,This medication may impair your ability to drive or operate machinery; avoid such activities until you know how it affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PERCORTEN vs DILAUDID-HP, answered by our medical review team.
PERCORTEN is a Mineralocorticoid that works by Percorten (desoxycorticosterone pivalate) is a synthetic mineralocorticoid that binds to and activates the mineralocorticoid receptor (MR) in the renal distal tubule, leading to increased sodium reabsorption, increased potassium and hydrogen ion excretion, and water retention, thereby expanding extracellular fluid volume and increasing blood pressure.. DILAUDID-HP is a Opioid Analgesic that works by Hydromorphone is a full mu-opioid receptor agonist with high affinity for mu-opioid receptors, producing analgesia, euphoria, and sedation. It also binds to kappa and delta opioid receptors with lower affinity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PERCORTEN and DILAUDID-HP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PERCORTEN is: 1-5 mg intramuscularly or subcutaneously daily with dose adjusted based on clinical response and electrolyte monitoring.. The standard adult dose of DILAUDID-HP is: Initial dose: 0.2-0.6 mg IV/IM/SC every 2-4 hours as needed; usual adult dose: 0.2-0.4 mg IV/IM/SC. Oral: 1-2 mg every 3-6 hours. Dose titration based on pain severity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PERCORTEN and DILAUDID-HP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PERCORTEN is classified as Category C. Percorten (desoxycorticosterone pivalate) is a mineralocorticoid. Data in pregnant women are limited. In animal studies, corticosteroids have been shown to be teratogenic. Use duri. DILAUDID-HP is classified as Category C. FDA Pregnancy Category C. First trimester: No well-controlled human studies; animal studies have shown teratogenicity at high doses. Second and third trimesters: Chronic maternal u. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.